Gonadorelin (GnRH)

It pairs a genuinely strong foundation with a borrowed headline and finicky execution. It is a real, formerly FDA-approved drug with a textbook-clear, reversible mechanism, and it is the master hormone of the reproductive axis. Those qualities lift it above many peptides. What caps it is that the use driving current demand, keeping the testes working on testosterone therapy, is extrapolated from hCG data rather than proven directly, per Hsieh 2013, the dosing is fragile because the half-life is minutes and the pattern must be pulsed, and most supply is compounded or grey-market. Get the dosing right and source it well and you sit at the upper end; navigate an awkward microdose schedule and uncertain supply and you sit at the headline score.

✅ Best for: TRT users with an intact pituitary who want to keep their testes working and preserve fertility, and who will commit to frequent, well-timed pulsed dosing; people who understand that hCG is the better-tested tool for the same fertility goal and are choosing gonadorelin deliberately, often during an hCG shortage; clinicians managing genuine hypothalamic amenorrhea who can deliver true pulses by pump for physiological, low-hyperstimulation ovulation, per Martin and Crowley 1990; clinicians inducing fertility in male hypogonadotropic hypogonadism who accept the logistical demands of pulsatile delivery, per Dwyer 2024.

❌ Avoid if: you want a set-and-forget injection, because the pulse pattern is the entire point and overly frequent dosing can suppress the axis, per Belchetz 1978; your pituitary itself is the problem, since gonadorelin needs a responsive pituitary downstream to work, per Zheng 2017; you cannot verify your source, because compounded and grey-market supply dominates and carries identity, sterility, and dose uncertainty; or you would be better served by the directly-tested hCG adjunct for the same goal, per Coviello 2005. For related melanocortin peptides outside this axis, see the PT-141 and Melanotan I reports.